Key clinical point: Among patients with episodic migraine, more than 4 years of preventive treatment with erenumab may be effective, safe, and well tolerated.
Major finding: Patients’ average number of monthly migraine days at study baseline was 8.7; the average change from baseline to the most recent month in the interim analysis was –5.8.
Study details: Interim analysis of data from 250 patients who received erenumab for the preventive treatment of migraine for more than 4 years in an open-label extension study.
Disclosures: The study was sponsored by Amgen, and several study authors are employees of Amgen or Novartis, the companies that market erenumab. Dr. Ashina is a consultant for Amgen, Novartis, and other companies.
Ashina M et al. AHS 2019, Abstract IOR10.